Although it is the leading infectious cause of birth defects, patients and some doctors know little about cytomegalovirus.

By a News Reporter-Staff News Editor at South Korea Daily Report-- Investigators discuss new findings in Herpesvirus Diseases ...

March 19, 2009 — Cytomegalovirus (CMV) glycoprotein B vaccine may help prevent maternal and congenital CMV infection, according to the results of a phase 2, randomized, double-blind, controlled trial ...

VANCOUVER, British Columbia—Cytomegalovirus (CMV) infection in kidney or kidney/pancreas transplant recipients occurs more frequently when alemtuzumab is used for induction instead of antithymocyte ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that, while often latent in the general population, can become reactivated in individuals with compromised immune systems. Inflammatory bowel disease ...

From February 2023, when the program began, to February 2024, 184 cases of congenital CMV infection or disease were identified among 60,115 infants screened using dried blood spot polymerase chain ...

Cytomegalovirus (CMV) is a ubiquitous member of the Herpesviridae family that can establish latent infections in humans but may reactivate to cause disease in both immunocompromised and, increasingly, ...

A VIRAL INFECTION THAT IMPACTS UP TO 5% OF BABIES. AND WE’RE GOING TO TALK ABOUT IT. LET’S TALK ABOUT IT WITH DOCTOR KRISTEN MOFFITT, AN INFECTIOUS DISEASE SPECIALIST AT BOSTON CHILDREN’S HOSPITAL.

Moderna Inc. said its vaccine to prevent cytomegalovirus, a common cause of birth defects, failed to meet its goal in a late-stage trial, a setback for the company still struggling to move past the ...

Researchers from Monash University and the Lions Eye Institute have discovered a tissue protein that acts as a central ...

Researchers have uncovered a compelling potential link between a chronic gut infection caused by a common virus and the development of Alzheimer’s disease, shedding light on an unexpected contributor ...

Evaxion’s AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program ...